A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

Also called NCT03656744

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
HighTide Therapeutics (Hong Kong) Limited (from the registry)
Registry
  • NCT NCT03656744
Other papers using this trial's data
  • A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes Nature communications, 2021-09-17 DOI, PubMed 34535644, PMC8448729 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03656744. Randomized; quadruple masking; primary purpose treatment. Start 2018-11-26 (actual); primary completion 2020-02-07 (actual). Results posted on 2021-12-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Condition
Fatty Liver, Nonalcoholic
Condition
NAFLD
Condition
Nonalcoholic Fatty Liver Disease
Condition
Nonalcoholic Steatohepatitis
Condition
Digestive System Diseases
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
HTD1801
Intervention (Drug)
Placebo
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited (class: industry)

Record details

Record id
cardio:ct-nct03656744
Content hash
c35b4151bf812e89cdd542ae51c977d3212919a57f14e07adbdb873d0b7c19ac